Journal of Clinical Oncology
Articles in this Issue
Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis.
LBA9504 Background: Neoadj immunotherapy improves outcomes in high-risk resectable mel, although novel combinations that enhance efficacy while minimizing...
Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: Results of a multicenter, double-blind, randomized phase II trial.
LBA2000 Background: The standard STUPP regimen (radiotherapy with temozolomide [TMZ] followed by adjuvant TMZ) remains lim...
ENLIGHTED phase 3 study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC).
LBA4513 Background: Padeliporfin VTP has demonstrated safety and efficacy for UTUC treatment in a Phase 1 study (NCT03617003). Padeliporfin VTP is a combi...
ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).
LBA5507 Background: Relacorilant is an investigational, oral, selective glucocorticoid receptor antagonist (SGRA) that increases tumor sensitivity to chem...
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013).
LBA9507 Background: While anti-PD-1 and anti-CTLA4 immunotherapies have efficacy in the treatment of patients (pts) with asymptomatic melanoma brain metas...
Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.
LBA4002 Background: T-DXd 6.4 mg/kg is approved for pts with metastatic HER2+ GC/GEJA who received a prior trastuzumab-based regimen based on prior phase...
Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with <i>RAS</i> and <i>BRAF</i> wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.
LBA3515 Background: Retreatment (re-tx) with anti-EGFR monoclonal antibodies offers a promising approach to extend the continuum of care...
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).
LBA1005 Background: Standard first line therapy in ER+/ HER2 negative endocrine sensitive metastatic breast cancer (MBC) i...
NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.
LBA4175 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with a median overall...
PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial.
LBA6003 Background: This study aimed to assess the efficacy and safety of toripalimab combined with induction chemotherapy and radiotherapy alone in locor...
Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.
LBA9500 Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free s...
Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.
LBA8008 Background: Tarlatamab, a bispecific T-cell engager (BiTE) immunotherapy, demonstrated promising activity in patie...
FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).
LBA5506 Background: The FIRST/ENGOT-OV44 trial evaluated adding dost, a programmed cell death protein-1 inhibitor, to 1L platinum-based chemotherapy (PBCT...
PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
LBA8671 Background: Effective therapy after frontline immune checkpoint inhibitor (ICI)-based treatment for advanced NSCLC...
Lower-dose versus standard-dose abiraterone in patients with metastatic castration resistant prostate cancer: A multicentric randomized phase III non-inferiority trial.
LBA5078 Background: Abiraterone Acetate (AbA), a novel hormonal agent, is commonly used in patients with metastatic prostate cancer. However, the standard...
Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial.
LBA5501 Background: Limited data is available on survival outcomes following sentinel lymph node biopsy (SLNB) as a substitute for pelvic lymphadenectomy...
Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial.
LBA9508 Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardle...
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.
LBA1008 Background: DESTINY-Breast09 (NCT04784715) is a global, randomized Phase 3 study assessing the efficacy and safety of 1L T-DXd ± P vs THP in 1157...
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
LBA1000 Background: Vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) ER degrader, showed encouraging clinical...
Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).
LBA3509 Background: Systemic inflammation has been implicated in colon cancer progression. We examined whether intake of a proinflammatory diet is associa...
Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
LBA8000 Background: NIVO + chemo is an established standard of care neoadjuvant treatment (tx) for eligible patients (pts) with resectable NSCLC and has s...
An open label randomized non-inferiority trial comparing adjuvant platinum plus paclitaxel to platinum plus 5-FU after curative resection in high-risk penile carcinoma.
LBA5012 Background: There is limited evidence to guide adjuvant therapy in high-risk penile cancer. Methods: Patients with high-ri...
CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)—A randomized, single-blind, multicenter phase 3 study.
LBA8502 Background: Anti-PD-(L) 1 monotherapy has been the standard first-line treatment for PD-L1 positive NSCLC, but its clinical benefit remains unsati...
Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and <i>MET</i> -amplification ( <i>MET</i> amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
LBA8505 Background: Savo, a highly selective MET -TKI, combined with osi, may over...
A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.
LBA9505 Background: Advances in the neoadjuvant (neo) setting of locoregionally advanced melanoma have recently transformed practice. However, there conti...